Results 31 to 40 of about 12,575 (207)

Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women [PDF]

, 2015
Contains fulltext : 153646.pdf (Publisher’s version ) (Open Access)OBJECTIVES: To describe the pharmacokinetics of darunavir in pregnant HIV-infected women in the third trimester and post-partum.
Hawkins, D., Weizsacker, K., Ende, M. van der, Taylor, G., Molto, J., Gingelmaier, A., Sadiq, S.T., Colbers, A., Burger, D.M., Warris, A., Ivanovic, J., Kabeya, K., Giaquinto, C., Ven, A.J.A.M. van der, et al.   +14 more
core   +3 more sources

Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis

HIV Research & Clinical Practice, 2021
Background: Treatment during acute or early human immunodeficiency virus (HIV)-1 infection is associated with immunologic and virologic benefits. Objective: To evaluate darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) efficacy/safety ...
Keith Dunn, Rachel Rogers, Richard Bruce Simonson, Donghan Luo, Shubin Sheng, Purnima T. Kassam, Sareh Seyedkazemi, Hélène Hardy   +7 more
doaj   +1 more source

The Effect of Solvents and Drying Temperature on the Physicochemical Properties of Darunavir and Darunavir Ethanolate Substances

Разработка и регистрация лекарственных средств, 2021
Introduction. Usage of aggressive conditions (solvents, high temperature, etc.) in a dosage form manufacturing can lead to a change in the properties of a pharmaceutical substance.
S. A. Zolotov, I. A. Dain, N. B. Demina, A. S. Zolotova, E. S. Ponomarev   +4 more
doaj   +1 more source

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial

AIDS Research and Treatment, 2012
Objectives. Evaluation of pharmacokinetics and pharmacodynamics of darunavir and etravirine among HIV-1–infected, treatment-experienced adults from GRACE, by sex and race. Methods.
Thomas Kakuda, Vanitha Sekar, Peter Vis, Bruce Coate, Robert Ryan, David Anderson, Guy De La Rosa, Joseph Mrus   +7 more
doaj   +1 more source

Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States

AIDS Research and Therapy, 2021
Introduction Although individual antiretroviral drugs have been shown to be associated with elevated cardiovascular disease (CVD) risk, data are limited on the role of antiretroviral drug combinations.
Kunchok Dorjee, Manisha Desai, Tsering Choden, Sanjiv M. Baxi, Alan E. Hubbard, Arthur L. Reingold   +5 more
doaj   +1 more source

Pharmacological aspects of darunavir/cobicistat [PDF]

, 2016
Rezolsta® (darunavir/cobicistat) es el primer inhibidor de la proteasa potenciado en combinación fija con un nuevo potenciador farmacológico. Darunavir es actualmente el inhibidor de la proteasa de uso preferente con un perfil de eficacia y seguridad ...
Santos-González, Jesús Leandro, González-Doménech, Carmen María, Palacios-Muñoz, María Rosario   +2 more
core   +1 more source

A novel simultaneous high performance liquid chromatography-PDA method for the determination of Tenofovir AF, Darunavir, Emtricitabine and Cobicistat in bulk and its application to marketed formulation

Future Journal of Pharmaceutical Sciences, 2022
Background The present research article involves the simultaneous determination of Tenofovir alafenamide, Darunavir, Emtricitabine and Cobicistat in bulk as well as in tablet dosage form using high performance liquid chromatography. Result The separation
Challamalla Pavani, E. Susithra
doaj   +1 more source

Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study

Current Issues in Molecular Biology, 2022
Candida albicans is the chief etiological agent of candidiasis, a mycosis prevalent in individuals with acquired immunodeficiency syndrome (AIDS). In recent years, the introduction of human immunodeficiency virus (HIV) protease inhibitors (HIV-PI) has ...
Juliana de C. Fenley, Patrícia P. de Barros, Paulo H. F. do Carmo, Maíra T. Garcia, Rodnei D. Rossoni, Juliana C. Junqueira   +5 more
doaj   +1 more source

Risk factors contributing to a low darunavir plasma concentration [PDF]

, 2017
Darunavir is an efficacious drug; however, pharmacokinetic variability has been reported. The objective of this study was to find predisposing factors for low darunavir plasma concentrations in patients starting the once- or twice-daily dosage. Darunavir
Touw, Daan J.; id_orcid, Ymkje Stienstra, Touw, Daan J., Alffenaar, Jan Willem C., Jos G. W. Kosterink, Daan J. Touw, Wouter F. W. Bierman, Kosterink, Jos G.W., Kosterink, Jos G.W.; id_orcid, Bierman, Wouter F.W., Jan-Willem C. Alffenaar, Daskapan, Alper, Stienstra, Ymkje, van der Werf, Tjip S., Alper Daskapan, Tjip S. van der Werf   +15 more
core   +1 more source

Pharmacokinetic Interactions of Maraviroc with Darunavir-Ritonavir, Etravirine, and Etravirine-Darunavir-Ritonavir in Healthy Volunteers: Results of Two Drug Interaction Trials [PDF]

, 2011
The effects of darunavir-ritonavir at 600 and 100 mg twice daily (b.i.d.) alone, 200 mg of etravirine b.i.d. alone, or 600 and 100 mg of darunavir-ritonavir b.i.d. with 200 mg etravirine b.i.d.
Noella Ndongo, Caroline Ridgway, Rebecca Mack, Samantha Abel, Julia Hamlin, Sarah Tweedy, Thomas N. Kakuda, John Davis, Monika Schöller-Gyüre, Wendy Petit, Vanitha Sekar, Richard M. W. Hoetelmans   +11 more
core   +1 more source